Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...

Novo Nordisk has announced headline results from a late-stage study of its obesity candidate CagriSema in adults with type 2 diabetes (T2D). The phase 3 REDEFINE 2 trial has been evaluating ...